RAPIvD develops patented reusable pregnancy device

News Release

23:06:2023

RAPIvD develops patented reusable pregnancy device  

Rapid in vitro diagnostics specialist, RAPIvD Ltd, has assisted with the invention of a reusable pregnancy device for Swedish company, Pharmista Technologies. The device, which is hailed as one of the most important developments in pregnancy diagnostics in the last 30 years, has been granted a patent in Sweden by the Swedish Patent Office as well as being acknowledged by the European Patent Office for its patentability under the Patent Cooperation Treaty.

Current pregnancy test kits are single use, can be expensive and accuracy varies widely across brands. The Pharmista platform aims to disrupt the sector with a hygienic, accurate and reusable product.

Scientists from RAPIvD have been instrumental in developing the concept of using molecular imprinted polymers (MIPs) as a replacement for conventional binding partners. Unlike antibodies, MIPs can be reused after cleansing and have the capacity for a shelf life of many years.

RAPIvD CEO, Dr Robert Porter said. “We’ve helped Pharmista to develop a product that overcomes many of the weaknesses associated with existing devices available on today’s market. The convenience, accuracy, cost effectiveness and longevity of the product will give it a fantastic opportunity to make a significant impact on the pregnancy diagnostics sector”.

Pharmista Technologies’ CEO, Alice Mattsson said. “Acknowledgement from the European Patent Office and obtaining our patent in Sweden was a major step in our product development plan. Pregnancy testing is the launchpad for our technology platform that we hope will make many single-use in vitro diagnostics devices obsolete in the next decade”.

Ends.

Links:

RAPIvD: RAPIvD | Rapid IVD R&D | UK

Pharmista Technologies: Home | Pharmista Technologies